Onorach has been named as one of the fastest growing in a new analysis of the world's largest Medical & Clinical Research Companies. This reflects Onorach’s excellent performance over the past 12 months and readiness for the future.
What makes Onorach’s growth impressive is that it has been achieved in a difficult marketplace where 325 of competitors are in financial danger and a record number are making a loss.
The Plimsoll Analysis, which highlighted these findings, individually assessed the 1580 leading companies in the Global Medical & Clinical Research market. Plimsoll’s analysis model highlights the latest performance of each company. Plimsoll analysis is continuously updated to reveal each company’s current key strengths, what issues are developing within each business and how they have performed in each of the last 4 years.
Onorach’s C.E.O. Stephen Leiper commented “We are happy to see that our efforts over the last 12-18 months to grow Onorach are being recognised by industry analysts. We have spent a great deal of time and energy focusing on adding strength to our core clinical trial management offering as well as developing our products – such as our digital data capture system ‘encryptiDATA’ and entering new markets like Nutraceuticals. I am confident that our roadmap is the right one for Onorach and its successes are being noticed within the industry”.
Subscribe to RSS Feed